Skip to main content

Caboxen 20 mg & 80 mg ( Cabozantinib)

Caboxen is identified as a cabozantinib product available in 20 mg and 80 mg strengths. Cabozantinib is a prescription tyrosine kinase inhibitor used in specific cancer-treatment settings.

This page provides general prescribing information about cabozantinib, including its therapeutic classification, approved uses of established reference formulations, administration considerations, warnings, precautions, and monitoring requirements.

Important: The exact dosage form, manufacturer, and product-specific regulatory authorization of Caboxen have not been independently established here. Therefore, the prescribing information for another cabozantinib product must not automatically be treated as the official prescribing information for Caboxen.

1. Medicine Identification

InformationDescription
Product nameCaboxen
Active ingredient statedCabozantinib
Presented strengths20 mg and 80 mg
Therapeutic classAntineoplastic agent
Pharmacological classTyrosine kinase inhibitor
Route of administrationOral for established oral cabozantinib formulations
Exact dosage form–
Manufacturer–
Prescription statusCabozantinib is a prescription medicine

2. Therapeutic Indications

Cabozantinib is used for certain cancers, depending on the formulation and applicable regulatory approval.

Established reference indications include:

Advanced Renal Cell Carcinoma

Cabozantinib tablets are indicated for specified patients with advanced renal cell carcinoma. They may be prescribed alone or in combination with nivolumab as a first-line treatment in appropriate patients.

Hepatocellular Carcinoma

Cabozantinib tablets are indicated for certain patients with hepatocellular carcinoma who have previously received sorafenib.

Differentiated Thyroid Cancer

Cabozantinib tablets are indicated for eligible patients with locally advanced or metastatic differentiated thyroid cancer that has progressed following previous VEGFR-targeted therapy and is radioactive iodine-refractory or unsuitable for radioactive iodine treatment.

Neuroendocrine Tumors

Cabozantinib tablets have an indication for certain previously treated, unresectable, locally advanced, or metastatic well-differentiated pancreatic and extra-pancreatic neuroendocrine tumors.

Medullary Thyroid Cancer

A separate cabozantinib capsule formulation is indicated for patients with progressive, metastatic medullary thyroid cancer.

These indications are formulation-specific. They should not be interpreted as confirmation that Caboxen is authorized for every listed condition.

3. Dosage and Administration

Cabozantinib dosage depends on the cancer being treated, formulation, treatment regimen, and individual patient characteristics.

The prescribing oncologist determines the appropriate dose.

The following are reference regimens for established products, not dosing instructions for Caboxen.

Reference formulation and treatmentReference regimen
Cabozantinib tablets for advanced RCC as a single agent60 mg once daily
Cabozantinib tablets with nivolumab for advanced RCC40 mg once daily
Cabozantinib tablets for specified HCC treatment60 mg once daily
Cabozantinib tablets for specified DTC and NET treatment60 mg once daily in eligible adults
Cabozantinib capsules for progressive metastatic MTC140 mg once daily

Doses may require adjustment because of adverse reactions, liver impairment, or drug interactions.

Do not use the reference regimens above to determine a Caboxen dose. Its exact formulation and applicable prescribing instructions must first be confirmed.

4. Administration Instructions

Administration requirements differ between cabozantinib tablets and capsules.

Tablet Formulation

For the reference tablet product:

  • Take on an empty stomach.
  • Take at least 1 hour before or at least 2 hours after eating.
  • Swallow tablets whole.
  • Do not crush, chew, or split tablets.
  • Follow the prescribed schedule.

Capsule Formulation

For the reference capsule product:

  • Do not eat for at least 2 hours before taking the medicine.
  • Do not eat for at least 1 hour after taking the medicine.
  • Follow the prescribed capsule administration instructions.

These instructions are not interchangeable. Patients must follow the instructions for their confirmed formulation.

5. Contraindications

The reference US prescribing information for CABOMETYX tablets and COMETRIQ capsules lists no formal contraindications.

However, the absence of a listed formal contraindication does not mean cabozantinib is suitable for everyone.

A healthcare professional must evaluate individual risks, medical history, pregnancy status, other medicines, and treatment requirements before prescribing it.

6. Important Warnings and Precautions

Cabozantinib may cause serious adverse reactions. Patients require careful assessment before and during treatment.

Hemorrhage

Cabozantinib may cause severe or potentially fatal bleeding.

Patients with a recent history of significant bleeding require careful medical evaluation. The reference tablet prescribing information advises against administration in patients with a recent history of hemorrhage.

Gastrointestinal Perforation and Fistula

Cabozantinib may cause gastrointestinal perforation or fistula formation.

Patients should report severe abdominal pain, persistent gastrointestinal symptoms, or unusual passage of fluid or material between body structures.

Thromboembolic Events

Cabozantinib may increase the risk of arterial and venous blood clots.

Serious events can include heart attack, stroke, deep vein thrombosis, and pulmonary embolism.

Sudden chest pain, difficulty breathing, or one-sided leg swelling requires urgent medical evaluation.

Hypertension

High blood pressure may develop or worsen during treatment.

Blood pressure should be assessed before treatment and monitored regularly. Uncontrolled hypertension may require treatment interruption, dose adjustment, or discontinuation.

Diarrhea

Diarrhea may be severe and can lead to dehydration or other complications.

Patients should report persistent or severe diarrhea promptly.

Hand-Foot Skin Reaction

Cabozantinib may cause palmar-plantar erythrodysesthesia, commonly known as hand-foot skin reaction.

Symptoms may include redness, swelling, tenderness, pain, blistering, and peeling of the skin on the palms and soles.

Liver Toxicity

Liver-related abnormalities may occur during treatment.

Liver function should be evaluated before and periodically during treatment, particularly when cabozantinib is used with another anticancer medicine.

Proteinuria

Cabozantinib may cause protein to appear in the urine.

Urine protein should be monitored during treatment. Severe proteinuria may require treatment interruption or discontinuation.

Osteonecrosis of the Jaw

Osteonecrosis of the jaw is a serious condition involving damage to jawbone tissue.

Patients should inform their healthcare professional about dental problems and planned invasive dental procedures.

Impaired Wound Healing

Cabozantinib may interfere with normal wound healing.

The reference tablet prescribing information recommends withholding treatment before scheduled surgery and delaying resumption after major surgery until adequate wound healing has occurred.

Patients should discuss all planned surgical and dental procedures with their oncologist.

Reversible Posterior Leukoencephalopathy Syndrome

A rare neurological condition known as reversible posterior leukoencephalopathy syndrome (RPLS) may occur.

Possible symptoms include headache, seizures, confusion, visual disturbances, and other neurological changes.

Urgent medical assessment is necessary if these symptoms develop.

Embryo-Fetal Toxicity

Cabozantinib may cause fetal harm.

Women who could become pregnant should discuss effective contraception and pregnancy prevention requirements with their healthcare professional.

7. Drug Interactions

Cabozantinib is metabolized through the CYP3A4 pathway.

Medicines that strongly inhibit or induce CYP3A4 may change cabozantinib exposure.

Strong CYP3A4 Inhibitors

These medicines may increase cabozantinib exposure and potentially increase adverse reactions.

Examples include certain antifungal and antibiotic medicines.

CYP3A4 Inducers

These medicines may decrease cabozantinib exposure and potentially reduce its effectiveness.

Examples include certain medicines used for seizures and other conditions.

Patients should inform their healthcare professional about all prescription medicines, nonprescription products, supplements, and herbal preparations.

Dose adjustments may be required when certain interacting medicines cannot be avoided.

8. Use in Special Populations

Pregnancy

Cabozantinib may cause fetal harm. It should not be used during pregnancy unless specifically evaluated and directed under appropriate specialist guidance.

Breastfeeding

Patients should discuss breastfeeding with their healthcare professional. The reference prescribing information advises against breastfeeding during treatment and for the specified period after the final dose.

Liver Impairment

Patients with impaired liver function may require dose modification or may need to avoid treatment, depending on the severity of impairment and formulation.

Kidney Impairment

Patients with kidney problems require individualized assessment and appropriate monitoring.

Pediatric Patients

Pediatric use is limited to specific approved indications and age or weight requirements for the relevant tablet formulation. It should not be generalized to every cabozantinib product.

9. Monitoring During Treatment

Appropriate monitoring helps identify adverse reactions and assess treatment tolerance.

Healthcare professionals may evaluate:

  • Blood pressure.
  • Liver function.
  • Kidney function.
  • Urine protein.
  • Blood counts and relevant laboratory parameters.
  • Thyroid function.
  • Blood calcium levels.
  • Gastrointestinal symptoms.
  • Skin and hand-foot reactions.
  • Bleeding symptoms.
  • Wound healing.
  • Signs of blood clots.
  • Overall treatment response.

The frequency of monitoring depends on the patient’s condition, treatment regimen, and clinical findings.

10. Dose Modification and Treatment Interruption

The prescribing oncologist may temporarily interrupt treatment, reduce the dose, or permanently discontinue cabozantinib if serious or intolerable adverse reactions occur.

Dose modification may be necessary for:

  • Severe diarrhea.
  • Significant hand-foot skin reactions.
  • Uncontrolled hypertension.
  • Serious liver abnormalities.
  • Proteinuria.
  • Severe bleeding.
  • Gastrointestinal perforation or fistula.
  • Other clinically significant toxicities.

Patients must not make dose adjustments independently.

11. Missed Dose Information

Missed-dose instructions depend on the specific formulation and its prescribing information.

For the reference CABOMETYX tablet product, a missed dose should not be taken if the next dose is due within 12 hours.

Patients should follow the instructions for their actual medicine and contact their healthcare professional if they are uncertain.

Never take an extra dose to compensate for a missed dose unless specifically instructed by the prescribing professional.

12. Overdose

Taking more cabozantinib than prescribed may increase the risk of serious adverse reactions.

Patients should seek immediate medical advice if an overdose is suspected, even if no symptoms are present.

Do not attempt to manage a suspected overdose without professional guidance.

13. Storage and Handling

Store the medicine according to the instructions on its original packaging and applicable product information.

General precautions include:

  • Keep the medicine in its original container.
  • Protect it from unsuitable storage conditions.
  • Keep it away from children and pets.
  • Do not use expired medicine.
  • Do not use medicine with damaged or suspicious packaging.
  • Ask a pharmacist about appropriate disposal.

14. Product-Specific Information for Caboxen

The following information requires confirmation from the actual Caboxen packaging or official product documentation.

Product detailVerification status
Product nameIdentified as Caboxen
Active ingredientIdentified as cabozantinib
20 mg strengthPresented
80 mg strengthPresented
Dosage form–
Manufacturer–
Regulatory authorization–
Product-specific approved indications–
Official product prescribing information–

Important Prescribing Notice

This page is an educational overview and is not a substitute for the official prescribing information of a specific cabozantinib product.

Caboxen’s exact dosage form, manufacturer, regulatory status, and product-specific instructions must be verified before prescribing or using it. The prescribing information of reference tablet and capsule products must not be combined or treated as interchangeable.